RxDoctor Payments Data

John Vansavage, MD

Urology · Mayfield, KYNPI 1467457945

Payments from drug & device makers

What this record shows

24 manufacturers reported payments, led by Procept Biorobotics Corporation at 34.6% of the total. Reporting peaked in 2024 at $3,308 and has fallen 92.2% since, to $259 in 2025.

$9,341in general payments, 2019–2025

Across 143 payments — averaging $65.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Procept Biorobotics Corporation$3K
  • Boston Scientific$3K
  • Axonics, Inc.$2K
  • 180 Medical, Inc.$233
  • Lumenis, Inc$185
  • Astellas Pharma US Inc$184
  • plus $828 from 18 others

What the payments were for

  • Travel & lodging$5,42358%
  • Food & beverage$3,91842%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,341 in reported general payments places this provider in the 85th percentile of 139 urology providers in Kentucky.

See all urology providers in Kentucky

Medicare billing

Part B allowed, 2024
$113,996
Medicare patients
274
Services billed
1,340

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron260$157,941
Potassium Citrate ErPotassium Citrate152$14,488
Mirabegron ErMirabegron14$10,440
Oxybutynin Chloride ErOxybutynin Chloride445$9,729
Tamsulosin Hcl730$7,771
Estradiol82$5,428
Finasteride382$3,629
Testosterone Cypionate45$2,137
NitrofurantoinNitrofurantoin Macrocrystal56$1,844
Solifenacin Succinate29$1,677
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst99$1,489
Trospium Chloride21$1,427
Alfuzosin Hcl ErAlfuzosin Hcl18$325
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim69$246
Ketorolac Tromethamine24$220

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$184$157,941260 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 139 urology providers in Kentucky.

Other urology in Mayfield

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →